A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer by Gasa, Laura et al.
1SCIEnTIFIC REPORtS | 7: 10228  | DOI:10.1038/s41598-017-10770-8
www.nature.com/scientificreports
A systematic analysis of orphan 
cyclins reveals CNTD2 as a new 
oncogenic driver in lung cancer
L. Gasa1, A. Sanchez-Botet1, E. Quandt1, S. Hernández-Ortega1, J. Jiménez1, M. A. Carrasco-
García1,2, S. Simonetti1,2, S. J. Kron3, M. P. Ribeiro1, E. Nadal4, A. Villanueva5 & J. Clotet1
As lung cancer has increased to the most common cause of cancer death worldwide, prognostic 
biomarkers and effective targeted treatments remain lacking despite advances based on patients’ 
stratification. Multiple core cyclins, best known as drivers of cell proliferation, are commonly 
deregulated in lung cancer where they may serve as oncogenes. The recent expansion of the cyclin 
family raises the question whether new members might play oncogenic roles as well. Here, we 
investigated the protein levels of eight atypical cyclins in lung cancer cell lines and formalin-fixed and 
paraffin-embedded (FFPE) human tumors, as well as their functional role in lung cancer cells. Of the new 
cyclins evaluated, CNTD2 was significantly overexpressed in lung cancer compared to adjacent normal 
tissue, and exhibited a predominant nuclear location. CNTD2 overexpression increased lung cancer 
cell viability, Ki-67 intensity and clonogenicity and promoted lung cancer cell migration. Accordingly, 
CNTD2 enhanced tumor growth in vivo on A549 xenograft models. Finally, the analysis of gene 
expression data revealed a high correlation between elevated levels of CNTD2 and decreased overall 
survival in lung cancer patients. Our results reveal CNTD2 as a new oncogenic driver in lung cancer, 
suggesting value as a prognostic biomarker and therapeutic target in this disease.
Lung cancer is expected to be responsible for over 275,000 deaths in the European Union in the year of 2016, rep-
resenting more than 20% of total cancer mortality1. Around 80% of lung cancers are non-small-cell lung cancers 
(NSCLC), whose management remains challenging despite recent advances based on tumor genetic stratification 
using relevant biomarkers, such as EGFR, ALK, ROS-1, MET and KRAS2. While surgery or radiotherapy can 
cure early stage, localized tumors, high rates of local and distant relapse still occur3. Even then, the majority of 
NSCLC patients are not candidates for surgery due to their advanced or metastatic disease at diagnosis4. Despite 
progress in targeted therapies, most NSCLCs do not present known targetable mutations. Only one in five NSCLC 
patients respond to the approved checkpoint blockade immunotherapies5. Therefore, a deeper understanding of 
the molecular alterations underlying lung cancer development and progression may contribute not only to the 
identification of therapeutic targets, but also to the establishment of new prognostic and predictive biomarkers.
Loss of growth control is a hallmark of cancer and a common target of cancer therapeutics. Progression 
through the cell cycle is regulated by members of the cyclin-dependent kinase family (CDKs), a group of highly 
conserved serine/threonine kinases that must associate with cyclin proteins to phosphorylate their substrates6. 
Cyclin binding provides each CDK with targeting domains that mediate substrate binding and determine sub-
cellular localization, which in turn determine biological specificity. As such, specific cyclin-CDK complexes are 
associated with each major transition in the cell cycle. Many cancers display inappropriate expression of the 
canonical cell cycle cyclins. Here, they may serve as oncogenes by activating cell cycle CDKs to support deregu-
lated cancer cell proliferation. In the case of lung cancer, upregulation of cyclin B1, which binds CDK1 to drive 
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mitosis, was linked to a poor prognosis in NSCLC7. Likewise, decreased overall survival was observed in tumors 
overexpressing cyclin D1 which activates CDKs 4 and 6 in G1 phase8. In turn, EGFR inhibition downregulates 
cyclin D1, suggesting loss of cyclin-CDK activity may mediate effects of EGFR inhibitors9. Small molecules such 
as the approved agent palbociclib (Ibrance, Pfizer) and other cyclin D-CDK4/6 inhibitors demonstrate activity in 
multiple cancers including NSCLC, validating CDKs as therapeutic targets10, 11.
Most studies of lung cancer initiation and progression have limited their analysis to the canonical cyclins 
such as cyclin D, ignoring many other expressed genes that encode a characteristic “cyclin box”, the ~150 residue 
domain that determines CDK binding12, 13. While some of these “new” candidate cyclins are now known to bind 
the non-cell cycle CDKs that control transcription14, others remain “orphans”, where their CDK partner(s) remain 
to be identified15. Based on results from genetic model systems, some of these orphan cyclins are likely to serve 
regulatory roles in cell proliferation. Strikingly, the possible roles of non-canonical cyclins, including the orphan 
cyclins, remain largely unexplored in malignancies including lung cancer, and may lead to the development of 
innovative therapeutic strategies that complement cisplatin-based chemotherapy or CDK inhibitors.
Notably, previous analyses of altered gene expression in lung cancer have not identified orphan cyclins and 
being overexpressed or silenced. Nonetheless, the weak correspondence between the transcriptome and pro-
teome often observed in normal cells also presents significant challenges in lung cancer16. The discordance likely 
reflects the importance of post-transcriptional control in determining cellular protein levels17, 18. Given the many 
post-translational mechanisms that determine the abundance of canonical cyclins, we considered that a direct 
assessment of protein levels would be needed to detect altered expression of the orphan cyclins.
In the present work, we used immunodetection to probe expression of eight orphan cyclins in human lung 
cancer cell lines, as well as in resected NSCLC tumors and identified CNTD2 as commonly overexpressed in lung 
cancer. Studies in lung cancer cell lines and xenograft mouse models as well as patient data suggested altered 
expression of CNTD2 may have functional significance. Our work suggests that non-canonical cyclins such as 
CNTD2 have the potential to serve as oncogenes in lung cancer and have potential as prognostic markers in 
NSCLC.
Results
The expression of CNTD2 and CCNI is increased in lung cancer tissues. To investigate the potential 
role of orphan cyclins in lung cancer, the expression of CCNG1, CCNG2, CCNI, CCNO, CCNY, CNTD1, CNTD2 
and SPY1 was investigated in two lung adenocarcinoma cell lines, A549 and NCI-H1395, relative to a primary 
culture of human fibroblasts by Western blot (Fig. 1a) using antibodies validated against recombinant proteins 
(Supplementary Fig. S1). Examining expression of the canonical CCNA, as a positive control, revealed CCNA is 
up-regulated in both cancer cell lines, and particularly in A549 cells, relative to the normal fibroblasts (Fig. 1a). 
Expression of CNTD1, CNTD2 CCNG2, or SPY1 was undetectable in the tumor or normal cells (Supplementary 
Fig. S2a). However, compared to normal fibroblasts, expression of CCNY, CCNO and CCNG1 was higher in 
A549 cells while levels of CCNO, CCNG1 and CCNI were higher in NCI-H1395 cells (Fig. 1a). These results 
indicate that the expression of some orphan cyclins might be misregulated in lung cancer and that the pattern of 
their expression is cell type-specific. These observations were further supported by comparing the expression of 
orphan cyclins in NCI-H1395 cells and in the human lung fibroblast MRC-5 cell line (Supplementary Fig. S2b).
In order to further investigate the orphan cyclin expression in lung cancer, Western blot analysis was per-
formed in 43 formalin-fixed and paraffin-embedded (FFPE) human lung cancer samples and paired adjacent 
non-tumor lung tissue. Patient characteristics are summarized in Supplementary Table S1. The expression ratio 
between tumor and normal tissues (T/N ratio) was determined after normalization using Coomassie staining of 
the membrane. Median protein expression of CCNY, CCNO, CCNI, and CNTD2 was higher in lung cancer than 
normal lung tissue, but statistical significance was only found for CCNI and CNTD2 (Fig. 1b and c). The 17 kDa 
isoform of CNTD2 described by Uniprot was also expressed, but no difference was observed between normal and 
tumor tissue (data not shown).
Confirming the results obtained of Western analysis, examining six pairs of lung cancer and paired adjacent 
normal tissue by immunohistochemistry demonstrated positive staining for CNTD2, CCNO and CCNI while 
adjacent normal lung was generally negative (Fig. 2). A weak signal of CCNY was detected in both tumor and 
normal tissues (Fig. 2). CNTD2 was predominantly localized to the nuclei of tumor cells, while the CCNI local-
ized to the nuclear membrane and CCNO appeared concentrated in nucleoli.
Overexpression of CNTD2 and CCNI enhances the proliferation of lung cancer cells. To examine 
potential roles for orphan cyclins in cancer cell growth or survival, A549 cells were transduced with empty lentivi-
ral vector (control) or constructs expressing CCNI, CCNO, CCNY or CNTD2 (Fig. 3). Flow cytometry to detect 
GFP expression from lentivirus indicated an infection efficiency above 85% (data now shown) while Western blot 
confirmed overexpression (Fig. 3a). Cell viability evaluated by MTT assay 5 days after transduction revealed a sig-
nificant impact of CCNI and CNTD2 overexpression on cell viability (Fig. 3b). Suggesting an effect on cell prolif-
eration, A549 cells overexpressing CCNI and CNTD2 exhibited significantly higher Ki-67 staining (Fig. 3c and d). 
On the other hand, the expression of caspase-9 was monitored by western blot in A549 cells overexpressing 
CNTD2 and CCNI, and no significant alterations were found relative to control (Supplementary Fig. S3). 
Overexpression of CCNI and CNTD2 also increased clonogenicity of A549 cells, although statistical significance 
was only found for CNTD2 (Fig. 3e and f). Examining effects on cell survival, A549 cells overexpressing CCNI 
were also slightly less sensitive to cisplatin, gefitinib, and paclitaxel while overexpression of CNTD2 had little or 
no effect (Supplementary Fig. S4).
The overexpression of CNTD2 promotes lung cancer cell migration. To explore potential links 
between orphan cyclin expression and metastasis, we determined the T/N ratio for each cyclin in tumors from 
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patients with metastasis (M1) and without metastasis (M0). The T/N expression ratio of CCNO and CNTD2 was 
higher among patients with distant metastasis, but statistical significance was only found for CNTD2 (Fig. 4a). 
Although further studies with a large number of patients are required to confirm this observation, this explor-
atory investigation prompt us to test the potential effects of CNTD2 on cancer cell motility. For this purpose, 
confluent monolayers of A549 cells overexpressing CCNO or CNTD2 were scratched and wound closure deter-
mined 48 h later. A549 cells infected with empty vector were used as controls and reduced FBS media was used to 
suppress cell proliferation. As shown in Fig. 4b and c, migration of A549 cells overexpressing CNTD2 was signif-
icantly increased in comparison to control cells while CCNO did not significantly affect cell migration. Similarly, 
transwell assays demonstrated greater migration of A549 cells overexpressing CNTD2 to the lower chamber 
compared with control (Fig. 4d and e). Toward exploring potential mechanisms, we examined effects of CNTD2 
upregulation on expression of epithelial-to-mesenchymal transition (EMT) markers. A549 cells overexpressing 
CNTD2 expressed significantly lower levels of E-cadherin but N-cadherin was slightly increased (Supplementary 
Fig. S5), indicating CNTD2 might influence the EMT.
High levels of CNTD2 are associated with enhanced tumor growth in vivo and decreased overall 
survival of lung cancer patients. In order to investigate the effect of CNTD2 expression on lung cancer 
growth in vivo, we examined xenografts in nude mice formed by injection of A549 cells infected with empty 
Figure 1. CNTD2 and CCNI are overexpressed in human lung cancer tissues. The expression of orphan cyclins 
was evaluated by western blot analysis. (a) Representative images of the expression of orphan cyclins in human 
lung adenocarcinoma cell lines, A549 and NCI-H1395, and in normal fibroblasts. (b) The protein expression 
of orphan cyclins in human FFPE lung cancer tissues and paired-adjacent non-tumor lung tissue is presented 
as box plots of the expression ratio between tumor and normal lung tissues (T/N ratio), where the whiskers 
indicate the range of the data and the horizontal bars represent the median (n = 43). **P < 0.01, ***P < 0.001 
vs normal tissues, Wilcoxon test. (c) Representative images of the orphan cyclins protein expression in human 
normal (N) and tumor (T) FFPE lung tissue.
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vector (control) or overexpressing CNTD2. As shown in Fig. 5, A549 cells overexpressing CNTD2 formed faster 
growing tumors.
Finally, the prognostic value of CNTD2 gene expression in a large set of lung cancer patients was assessed. We 
used Kaplan-Meier Plotter to compare overall survival of patients stratified according to levels of CNTD2 expres-
sion. High CNTD2 expression correlated with reduced overall survival (Fig. 6a). A similar analysis of ovarian, 
Figure 2. Cellular location of overexpressed orphan cyclins in human lung tissues. Representative images of 
the immunohistochemical staining of human lung adenocarcinoma samples with CNTD2, CCNI, CCNY and 
CCNO antibodies. Adjacent normal tissues were used as a control. Magnification 60x. The square reveals a 
detail of a representative cell with a magnification of 100x.
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Figure 3. Overexpression of CCNI and CNTD2 increases the proliferation of A549 cells. A549 cells were 
infected with empty lentiviral vector (control) or with the indicated cyclin-overexpressing construct. (a) 
Western blot analysis confirmed cell infection (the asterisks show the expected band size). The flag indicates 
the protein expression level, the GFP the infection level and both the ponceau and the actin are used as loading 
controls. (b) A549 cell viability was evaluated by the MTT assay. Columns represent the mean ± SEM of five 
independent experiments performed in quadruplicates. ***P < 0.001 vs control, Mann-Whitney test. (c) The 
proliferation of A549 cells was evaluated by ki-67 immunostaining. Columns represent the mean ± SEM of four 
independent experiments. **P < 0.01 vs control, Mann-Whitney test. (d) Representative images of A549 cells 
immunostained for ki-67. Cell nuclei were counterstained with Hoechst 33258 and merged images are shown 
in the bottom row. (e) Efficiency of cell colony formation of A549 cells. Columns represent the mean ± SEM 
of four independent experiments performed in quintuplicates. **P < 0.01, vs control, Mann-Whitney test. (f) 
Representative images of the colony formation assay.
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breast, and gastric cancer revealed that high CNTD2 expression also predicted shorter overall survival but only 
for gastric cancer (Fig. 6b).
Discussion
The management of lung cancer remains a major challenge given that it is often diagnosed at an advanced stage of 
the disease that has a dismal prognosis. As the oncogenesis of lung cancer involves multiple molecular alterations, 
the development of new biomarkers would be helpful to guide treatment selection, as well as to avoid unnecessary 
toxicity and to improve the outcomes5. In the present study, we conducted an unbiased screening of the protein 
Figure 4. Overexpression of CNTD2 enhances the migration of A549 cells. (a) The T/N ratio of CCNO and 
CNTD2 was evaluated in FFPE lung tissue samples obtained from patients with (M1, n = 3) and without 
metastasis (M0, n = 40) and is represented as box plots. *P < 0.05, when compared to normal tissues, Mann-
Whitney test. (b) The migration of A549 cells was evaluated by the wound assay and the results are expressed 
as wound closure in µm. The columns represent the mean ± SEM of three independent experiments performed 
in triplicates. **P < 0.01 vs control, Mann-Whitney test. (c) Representative images of the wound assay were 
acquired at 0 and 48 h; the dotted lines define the areas lacking cells. (d) A549 cell migration was monitored by 
the transwell assay and estimated by quantifying the crystal violet staining intensity measured as the absorbance 
at 595 nm. The columns represent the mean ± SEM of four independent experiments performed in triplicate. 
*P < 0.05 vs control, Mann-Whitney test. (e) Representative images of the transwell assay after crystal violet 
staining.
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levels of eight orphan cyclins in lung cancer tissues, which revealed that some are deregulated and might be 
important factors in lung cancer development.
In our samples of FFPE tissues, we were unable to detect the expression of CCNG1, CCNG2, CNTD1 and 
SPY1 (Supplementary Fig. S2a). Interestingly, the Kaplan-Meier plots indicate that the overexpression of these 
cyclins is not associated with a worse prognosis of lung cancer patients (Supplementary Fig. S6a). On the con-
trary, high levels of CCNG1 were correlated with an increased overall survival of these patients (Supplementary 
Fig. S6a), pointing the high expression of CCNG1 as a good prognostic factor in lung cancer.
Moreover, according to the Kaplan-Meier Plotter database, CCNO upregulation is significantly associ-
ated with a reduced overall survival of lung cancer patients (Supplementary Fig. S6a), suggesting that CCNO 
is another orphan cyclin involved in the malignancy of the disease. However, we could not find a correlation 
between CCNO overexpression and the proliferation phenotype or the migration ability in A549 cells (Figs 3 
and 4); indeed, although the upregulation of CCNO slightly increases the migration of A549 cells, no statistical 
significance was found in our experimental setting (Fig. 4). Taken together, these results indicate that CCNO 
might be implicated in processes other than the proliferation and migration of lung cancer cells. Accordingly, it 
was reported that CCNO is an important element for the physiology of lungs, and that mutations in the CCNO 
gene result in congenital lung disease affecting the multicilliated lung cells19.
In the present study, we found no statistical difference regarding the expression of CCNY in healthy and tumor 
tissues (Fig. 1b and c). In line with this observation, the expression of this protein does not correlate with the 
overall survival of lung cancer patients (Supplementary Fig. S6a), suggesting that CCNY might not play a role in 
lung cancer disease. On the other hand, the role of CCNY is clearly established in certain tumors, such as glioma20 
and ovarian cancer21 indicating that its role in tumorigenesis might be tissue-specific. While previous reports 
have shown that CCNY is overexpressed in samples obtained from NSCLC patients22, we were unable to detect 
overexpression of CCNY in our samples (Fig. 1b and c). Since the work conducted by Yue et al.22 determined the 
Figure 5. CNTD2 overexpression significantly enhances tumor growth in vivo. (a) The tumor volumes were 
measured at the indicated number of days after mice were transplanted with A549-empty vector (control) and 
A549-CNTD2 (n = 7). *P < 0.05, vs control, Mann-Whitney test. (b) At day 62, the tumors were resected and 
weighed. *P < 0.05, vs control, Mann-Whitney test. (c) Representative images of the tumors resected at day 62 
obtained from A549-empty vector (control) and A549-CNTD2 cell-transplanted mice.
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levels of CCNY mRNA, while we measured the protein levels, these conflicting results may reflect the different 
readouts, in agreement with the observation that the protein expression in lung adenocarcinomas does not always 
correlate with the levels of the corresponding mRNA16, highlighting the importance of measuring the protein 
levels in this disease.
Our study detected that CCNI is upregulated at the protein level in human samples of NSCLC (Fig. 1b and c). 
Moreover, the overexpression of this cyclin increased the proliferation of A549 cells, as suggested by the results 
of the MTT assay (Fig. 3b) and ki-67 staining (Fig. 3c and d), unveiling a role for this cyclin in lung cancer cell 
proliferation. Interestingly, CCNI overexpression was also associated with worse response to anticancer agents 
(Supplementary Fig. S4), which is in agreement with the observation that CCNI promotes resistance to cispla-
tin in cervical cancer23. In our study, the resistance provided by CCNI seems to be unrelated with the chemical 
structure of the drugs, and further studies are now warranted to clarify whether multidrug resistance proteins 
might be implicated in this response. Moreover, CCNI was linked to angiogenesis in ovarian24 and breast can-
cers25, suggesting that its role in cancer may go beyond cell proliferation. Remarkably, the Kaplan-Meier analysis 
did not find a correlation between CCNI overexpression and the overall survival of lung cancer patients of all 
histopathological types, but statistical significance could be found when the same analysis was performed only in 
Figure 6. Prognostic value of CNTD2 on lung cancer survival. Kaplan-Meier plots were built using the Kaplan-
Meier plotter software (http://kmplot.com/lung/). The overall survival of (a) lung cancer (n = 726) and (b) 
gastric cancer patients (n = 867) of all subtypes expressing different levels of CNTD2 is shown. Red colored 
lines represent the patients with high gene expression, while black colored lines represent patients with low gene 
expression. The hazard ratio (HR) with 95% confidence intervals, as well as the logrank P-values are shown.
www.nature.com/scientificreports/
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patients with adenocarcinoma (Supplementary Fig. S6b). Given the variability in lung cancers, it is plausible that 
CCNI may have a relevant role in some lung cancer subtypes; indeed, the two adenocarcinoma cell lines analyzed 
display significant differences regarding CCNI expression relative to normal human fibroblasts (Fig. 1a).
Our results show that CNTD2 is important for both the proliferation and migration of A549 cells (Figs 3 and 4), 
and suggest that it may enhance lung cancer cell migration by promoting the EMT (Supplementary Fig. S5). The 
association between CNTD2 expression and a more aggressive phenotype was further corroborated by the results 
obtained in vivo (Fig. 5), as well as by the dramatic correlation between high levels of CNTD2 and a decreased 
overall survival of a large set of lung cancer patients (Fig. 6).
Interestingly, our results represent a new piece of information that has remained undetected by the analy-
sis of large-scale genomic datasets screenings, such as the one provided by the web-based resource cBioPortal 
for Cancer Genomics (http://cbioportal.org26), which reported a low frequency of CNTD2 alterations in cancer. 
Likewise, the website-based software Kaplan-Meier Plotter (http://kmplot.com/lung/27) indicates similar levels of 
mRNA of CNTD2 in normal and lung cancer tissues. On the other hand, the Oncomine database (http://www.
oncomine.org) demonstrates that high levels of CNTD2 mRNA are present in lung cancer tissues (Supplementary 
Fig. S7a), in line with our findings (Fig. 1b and c). Although we did not measure the levels of mRNA in our sam-
ples, these conflicting evidences reinforce the need to monitor the final product of gene expression, rather than 
the intermediate.
Strikingly, we were unable to detect CNTD2 protein expression in lung cancer cell lines (Supplementary 
Fig. S2a). According to the Expression Atlas database (https://www.ebi.ac.uk), CNTD2 is expressed in a few lung 
cancer cell lines (Supplementary Fig. S7b). While A549 cells present low levels of mRNA, the NCI-H1395 cells are 
among those showing higher levels of CNTD2 mRNA (Supplementary Fig. S7b), but the level of protein expres-
sion is still not appreciable to allow the antibody detection (Supplementary Fig. S2a). Such observations may 
suggest that CNTD2 expression is differentially regulated in cultured cells as compared with tissues.
CNTD2 is probably the less characterized of the orphan cyclins. While little is known about the cellu-
lar functions of CNTD2, its predominant nuclear location (Fig. 2) may implicate CNTD2 in transcription 
regulation as described for other cyclins. On the other hand, its name (CNTD2 stands for Cyclin N-terminal 
domain-containing protein 2) shows that this protein contains a cyclin box domain and, hence, that it might 
interact with some CDK. We have tried to detect the partners of CNTD2 by immunoprecipitation coupled to 
mass spectrometry, but we have not yet been able to identify any CNTD2-associated CDK (Ribeiro et al., unpub-
lished observations). Therefore, whether this still orphan cyclin performs its nuclear function alone or in associ-
ation with a CDK remains to be elucidated.
Here we report that CNTD2 is upregulated in human lung cancer tissues and correlates with worse prognosis. 
Our findings suggest that CNTD2 is an oncogenic driver in lung cancer, and further studies that may shed some 
light on the physiological and pathological role of CNTD2 are now warranted. Interestingly, CNTD2 does not 
seem to be expressed in normal tissues28, suggesting that this cyclin may represent a specific target for future 
therapies. The identification of CNTD2 interactors would possibly pave the way for the development of new 
therapeutic strategies targeting CNTD2.
Methods
Clinical samples. Lung cancer tissue samples and adjacent non-tumor lung tissue were obtained from 43 
patients diagnosed with NSCLC at the Hospital Universitari General de Catalunya and Hospital Universitari 
Sagrat Cor. For inclusion in this study, a patient must have had a diagnosis of primary lung cancer and did not 
receive chemotherapy or radiation therapy before surgery. The samples were fixed in formaldehyde and embed-
ded in paraffin (FFPE) according to routine procedures at these hospitals. Histologically, the tumors were classi-
fied according to the 2015 World Health Organization histologic classification of lung cancers and were reviewed 
by the same pathologist. Among the 43 samples, 28 were adenocarcinomas and 15 were squamous cell carcino-
mas. The tumors were staged using the TNM staging system and the patients’ characteristics are summarized in 
Supplementary Table S1. This study was approved by the Comitè Étic de Investigació Clínica (CEIC) de idcsalud 
Hospital General de Catalunya and carried out in accordance with the approved guidelines. The requirement to 
obtain informed consent was waived by the Ethics Committee because of the retrospective nature of the study, but 
an informed consent was obtained from living patients.
Cell lines and Reagents. The human lung adenocarcinoma cell lines A549 (purchased in 2014 from 
Sigma-Aldrich) and NCI-H1395 (purchased in 2016 from ATCC) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM; Sigma-Aldrich). The human lung fibroblast cell line MRC-5 was purchased from ATCC in 
2016 and cultured in Eagle’s Minimum Essential Medium (ATCC). Cells were used for no more than 5 passages 
after thawing. The media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich) 
and 1% penicillin/streptomycin (Sigma-Aldrich). The cells were kept at 37 °C in a humidified incubator with 5% 
CO2. Cisplatin, paclitaxel and gefitinib were purchased from Sigma-Aldrich. Mycoplasma contamination was 
monitored periodically.
Protein extraction from FFPE tissues. Sample blocks consisting of >80% tumor tissue were selected 
along with paired normal controls. Following standard methods for protein extraction29, 30, tissue sections (10 
μm) were deparaffinized and rehydrated. After incubation on ice with 100 µl of lysis buffer (20 mM Tris-HCl 
pH = 8.8, 200 mM DTT, 2% SDS) for 5 min, and placed at 100 °C for 20 min. Then, samples were placed on a 
thermomixer for 2 h, at 80 °C and 750 rpm. Afterwards, the samples were centrifuged at 14,000 rpm for 15 min at 
4 °C, and the supernatant was collected for subsequent analysis.
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Protein extraction from human cell lines. Cultured human cell lines were washed with ice-cold 
phosphate-buffered saline (PBS) and placed on lysis buffer, containing 20 mM TRIS, 5 mM EDTA, 1% NP40 
(IGEPAL CA-630), 150 mM NaCl, pH 7.4, supplemented with Pierce Phosphatase Inhibitor Mini tablets (#88667, 
Thermo Fisher Scientific) and with Pierce Protease Inhibitor tablets (#88266, Thermo Fisher Scientific). Extracts 
were sonicated and centrifuged at 14,000 rpm for 15 min at 4 °C, and the supernatants collected.
Western blot analysis. Protein concentration was quantified by Bradford assay (BioRad). Gel samples 
were denatured at 90 °C for 5 min and 25 µg of total protein was separated by 10% SDS-PAGE and transferred to 
PVDF membranes (Immobilon-P, Millipore). All the information regarding the commercial primary antibodies 
used is indicated in Supplementary Table S2. After blocking, the membranes were incubated with the primary 
antibody in TBS-T + 5% non-fat milk overnight at 4 °C. After extensive washing, membranes were incubated 
with horseradish peroxidase (HRP) conjugated anti-mouse, -rabbit, and -goat IgG secondary antibodies (Jackson 
Laboratories) for 1 h at room temperature. After additional washes, the membranes were developed using 
Luminata Forte Western HRP Substrate (Millipore) following manufacturer’s instructions, and images were taken 
with GeneSnap (Syngene). The density of the bands was analyzed using the Image Studio Lite (Li-Cor) software.
Validation of antibodies. Human orphan cyclins were cloned in pGBKT7 vector (Clontech) as Gal4 
DNA-binding domain (DNA-BD) fusion proteins, which were expressed in the yeast strain AH109. Western blot 
analysis against both the Gal4 DNA-BD and the corresponding cyclin confirmed the validity of the antibodies 
(Supplementary Fig. S1).
Immunodetection. Immunohistochemical staining of FFPE samples was performed on 4 µm sections using 
a BenchMark Ultra (Ventana Medical Systems Inc.). The following polyclonal antibodies were used: CNTD2 
(ab179781, Abcam) at a dilution of 1:100; CCNO (ab47682, Abcam) at a dilution of 1:100; CCNI (H-279, Santa 
Cruz Biotechnology) at a dilution of 1:50; and CCNY (ab114086, Abcam) at a dilution of 1:100. The sections were 
introduced in the stainer and automatically deparaffinized with the reactive EZ-PREP and treated with CC2 cell 
conditioning 6.1 for antigen retrieval for 30 min at 95 °C. After incubation with antibodies, immunoreactivity was 
detected with Kit uView DAB with diaminobenzidine (DAB) as a chromogen and counterstained with hematoxy-
lin. Appropriate controls were included. For protein staining, two categories were recorded: negative and positive; 
only convincing staining was designated as positive.
For Ki-67 analysis, A549 infected cells were seeded on poly-L-lysine coated coverslips in 24 well plates at a 
density of 25,000 cells per well and, after 24 h, the cells were fixed in cold 4% paraformaldehyde at 4 °C for 15 min. 
Afterwards, the cells were blocked with PBS containing 0.1% Triton and 10% horse serum for 1 h, followed by 
incubation with Ki-67 antibody (556003, BD Pharmingen) diluted at 1:200 for 1 h at room temperature. The 
coverslips were washed several times with PBS and incubated for 1 hour at room temperature with anti-mouse 
fluorescent secondary antibody at 1:1,000 dilution in the dark. After additional washes with PBS, the nuclei were 
counterstained with Hoechst 33258 (14530, Sigma-Aldrich) and the slides coverslipped. Image analysis was per-
formed using NIS-Elements AR 4.13.04 software. Between 50 and 70 cells were analyzed per condition.
Viral cloning and transduction. To engineer lentiviral constructs expressing the cyclins under investi-
gation, human cDNA of CCNO, CCNI and CCNY were amplified from HT-29 cells with a C-terminal FLAG 
tag. CNTD2 was purchased as a gBlock (IDT) based on Ensembl sequence ENST00000430325.6. The primer 
sequences used in this study are indicated in the Supplementary Table S3.
All the sequences were cloned into pWPI lentiviral expression vector (#12254, Addgene) at the PmeI restriction 
site. For lentivirus production, 45 μg of lentiviral expression vector were cotransfected with 12.9 μg of pMD2.G 
and 29.1 μg of psPAX2 into HEK293-T cells in 10 cm plates using calcium phosphate. The virus-containing super-
natant was collected at 24 h and 48 h post-transfection, and concentrated using the Sartorius VS2042 Vivaspin 20 
concentrator (Sartorius) and the viral titer determined. For overexpression studies, A549 cells were infected with 
10 MOI of lentivirus.
Cell viability and colony formation assays. Cell viability was evaluated by MTT assay. Cells were grown 
in 48 well plates at a density of 1,500 cells per well. Seventy-two hours later, the cells were infected, and after 5 
days the cells were incubated with MTT solution (Sigma) for 1 h, at 37 °C. Formazan crystals were dissolved in 
DMSO and quantitated by measuring the absorbance in a Synergy HT plate reader at 570 nm. The reduction of 
MTT is expressed as percentage of the absorbance value obtained in the control which was considered 100%. 
For experiments using anti-cancer agents, cells were seeded in 24 well plates at a density of 60,000 cells per well, 
and after 24 h the cells were treated with cisplatin, paclitaxel, or gefitinib. MTT assay was performed as described 
above 72 h later.
For colony formation assay, A549 cells were seeded into 6 well plates at a density of 100 cells per well and 
cultured for two weeks. Colonies were fixed with 100% cold methanol, washed with PBS and stained with 0.1% 
crystal violet for 30 min at room temperature. The number of colonies was determined and survival calculated as 
a percentage of the control.
Wound healing and transwell migration assays. For wound healing assay, cells were seeded into 24 
well plates at a density of 2.5 × 105 of cells per well and grown to confluency. The cell monolayer was scratched 
with a 10 µl pipette tip, washed with PBS to remove detached cells from the plates, and incubated in DMEM con-
taining 0.5% FBS. Images were acquired at 0and 48 h under a 4× magnification and the distance between one side 
of the wound and the other was measured using ImageJ. Cell migration was determined by calculating the wound 
closure, which corresponds to the difference between the size of the wound at 0 h and at the indicated time point, 
and it is expressed as µm.
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For migration assays, cells were seeded into the upper chamber of an 8 µm pore size insert (Corning) in an 
uncoated 24 well plate at a density of 5 × 104 cells per well. The cells were cultured in DMEM containing 0.5% 
FBS, and allowed to migrate to the lower compartment containing DMEM 10% FBS for 18 h. The nonmigratory 
cells on the surface of the upper chamber were removed with a cotton tip, and the migratory cells attached to the 
lower membrane surface were fixed with cold methanol for 15 min at 4 °C and stained with 0.1% crystal violet 
for 30 min at room temperature. Cells were imaged under a 10× objective. To estimate the number of cells in the 
lower compartment, the crystal violet dye was dissolved using acetic acid at 10% and absorbance was measured 
at 595 nm. The crystal violet staining intensity is expressed as percentage of the absorbance value obtained in the 
control which was considered 100%.
Tumor xenografts. Athymic nude mice male (Crl:NU-Foxn1nu) (n = 7) at 5-weeks-old male (Envigo, 
Italy) of age were subcutaneously injected in each flank with a total of 3 × 106 A549-empty vector or 
A549-CNTD2-transfected cells soaked in 100 µL of Matrigel (BD Biosciences). Tumor growth was monitored by 
measuring tumor width (W) and length (L) until mice were killed, 62 days after injection. After allowing them to 
grow for several weeks, tumor volume (mm3) was estimated from the formula V = π/(6 × L × W2) and at the mice 
sacrifice the tumors were dissected out and weighed (g). All mouse experiments were approved by the IDIBELL 
Animal Care Committee and the methods were carried out in accordance with the approved guidelines.
Kaplan-Meier analysis. For survival analyses, the overall survival of patients divided into low and high 
expression groups according to the median expression of the gene of interest was presented as Kaplan-Meier 
plots. The analysis was conducted as described (http://kmplot.com/lung/) selecting only patients with surgical 
margins negative and tested for significance by two-tailed log rank t test27.
Statistical analysis. Unless otherwise stated, data are represented as the mean ± standard error of the mean 
(SEM) with P-values: ***P < 0.001; **P < 0.01; *P < 0.05. Statistical significance was determined using the 
Mann-Whitney test, except for the expression ratio between tumor and normal tissues which was analyzed using 
the Wilcoxon test. Statistical analyses were conducted using GraphPad Prism 5 and the Statistical Package for the 
Social Sciences (SPSS) 21.
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